Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution from Idea to IND (I to I^TM), today announced that it has entered into a license agreement with Kelun-Biotech based on Nona’s proprietary fully human antibody transgenic mice platform Harbour Mice^® to discover novel fully human antibodies and develop innovative therapeutics including antibody-drug conjugate (ADC) drugs with Kelun-Biotech’s ADC technology. Under the terms of the agreement, Nona Biosciences shall receive upfront payments, milestone payments and sales-based royalties.

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed said: “This agreement enables us to leverage Nona’s great expertise in innovative biologics drug discovery and antibody platform application in the field of ADC drug development. We are pleased to continue the long-term cooperation with Kelun-Biotech, the leading ADC biotechnology company. The potential of both our proprietary platform and antibody discovery capabilities has been well recognized by a series of partners including the mRNA therapy giant Moderna, the world-leading NK-cell therapy pioneer Dragonfly Therapeutics, as well as the iconic ADC therapy innovator Kelun-Biotech. We will keep helping our partners generate differentiated therapeutic molecules benefiting the patient worldwide.”

Mr. Junyou Ge, CEO of Kelun-Biotech commented: “We aim to leverage Nona’s fully human antibody transgenic mice platform to obtain novel antibody molecules on specific targets and strive to develop innovative ADC drugs which can meet global needs better and faster.”

About Kelun-Biotech

Kelun-Biotech focuses on the research and development, production, marketing and international cooperation of biotechnology drugs and innovative small molecule drugs. Focusing on the unmet clinical needs , Kelun-Biotech focuses on the layout of major disease fields such as cancer, autoimmunity, inflammation and metabolic diseases, builds an international drug R & D and industrialization platform, and is committed to becoming an internationally leading enterprise in the field of innovation. Significant progress has been made in the field of biotechnology drugs, including ADC, bi-specific antibodies, and hot technologies for innovative small molecule drugs with new targets. Kelun-Biotech currently has more than 33 innovative projects for the treatment of major diseases such as tumors, autoimmunity, inflammation, and metabolic diseases, of which 14 projects enter clinical studies in China and 3 projects carry out clinical studies in the United States.

About Nona Biosciences

Nona Biosciences (a wholly-owned subsidiary of HBM Holdings, HKEX: 02142) is a global biotechnology company committed to providing a total solution from “Idea to IND” (“I to I^TM”), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice^® platforms and the experienced therapeutic antibody discovery team.

Harbour Mice^® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice^® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. More information, please check www.nonabio.com